Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.

CXCL8/interleukin-8 is a pro-inflammatory chemokine that triggers pleiotropic responses, including inflammation, angiogenesis, wound healing and tumorigenesis. We engineered the first selective CXCR1 agonists on the basis of residue substitutions in the conserved ELR triad and CXC motif of CXCL8. Ou...

Full description

Bibliographic Details
Main Authors: Jose Sarmiento, Christie Shumate, Katsutoshi Suetomi, Aishwarya Ravindran, León Villegas, Krishna Rajarathnam, Javier Navarro
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3235101?pdf=render
id doaj-6e37b22d42584ae894fe2e3cee0c32cd
record_format Article
spelling doaj-6e37b22d42584ae894fe2e3cee0c32cd2020-11-24T22:06:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01612e2796710.1371/journal.pone.0027967Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.Jose SarmientoChristie ShumateKatsutoshi SuetomiAishwarya RavindranLeón VillegasKrishna RajarathnamJavier NavarroCXCL8/interleukin-8 is a pro-inflammatory chemokine that triggers pleiotropic responses, including inflammation, angiogenesis, wound healing and tumorigenesis. We engineered the first selective CXCR1 agonists on the basis of residue substitutions in the conserved ELR triad and CXC motif of CXCL8. Our data reveal that the molecular mechanisms of activation of CXCR1 and CXCR2 are distinct: the N-loop of CXCL8 is the major determinant for CXCR1 activation, whereas the N-terminus of CXCL8 (ELR and CXC) is essential for CXCR2 activation. We also found that activation of CXCR1 cross-desensitized CXCR2 responses in human neutrophils co-expressing both receptors, indicating that these novel CXCR1 agonists represent a new class of anti-inflammatory agents. Further, these selective CXCR1 agonists will aid at elucidating the functional significance of CXCR1 in vivo under pathophysiological conditions.http://europepmc.org/articles/PMC3235101?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jose Sarmiento
Christie Shumate
Katsutoshi Suetomi
Aishwarya Ravindran
León Villegas
Krishna Rajarathnam
Javier Navarro
spellingShingle Jose Sarmiento
Christie Shumate
Katsutoshi Suetomi
Aishwarya Ravindran
León Villegas
Krishna Rajarathnam
Javier Navarro
Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.
PLoS ONE
author_facet Jose Sarmiento
Christie Shumate
Katsutoshi Suetomi
Aishwarya Ravindran
León Villegas
Krishna Rajarathnam
Javier Navarro
author_sort Jose Sarmiento
title Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.
title_short Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.
title_full Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.
title_fullStr Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.
title_full_unstemmed Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.
title_sort diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description CXCL8/interleukin-8 is a pro-inflammatory chemokine that triggers pleiotropic responses, including inflammation, angiogenesis, wound healing and tumorigenesis. We engineered the first selective CXCR1 agonists on the basis of residue substitutions in the conserved ELR triad and CXC motif of CXCL8. Our data reveal that the molecular mechanisms of activation of CXCR1 and CXCR2 are distinct: the N-loop of CXCL8 is the major determinant for CXCR1 activation, whereas the N-terminus of CXCL8 (ELR and CXC) is essential for CXCR2 activation. We also found that activation of CXCR1 cross-desensitized CXCR2 responses in human neutrophils co-expressing both receptors, indicating that these novel CXCR1 agonists represent a new class of anti-inflammatory agents. Further, these selective CXCR1 agonists will aid at elucidating the functional significance of CXCR1 in vivo under pathophysiological conditions.
url http://europepmc.org/articles/PMC3235101?pdf=render
work_keys_str_mv AT josesarmiento divergingmechanismsofactivationofchemokinereceptorsrevealedbynovelchemokineagonists
AT christieshumate divergingmechanismsofactivationofchemokinereceptorsrevealedbynovelchemokineagonists
AT katsutoshisuetomi divergingmechanismsofactivationofchemokinereceptorsrevealedbynovelchemokineagonists
AT aishwaryaravindran divergingmechanismsofactivationofchemokinereceptorsrevealedbynovelchemokineagonists
AT leonvillegas divergingmechanismsofactivationofchemokinereceptorsrevealedbynovelchemokineagonists
AT krishnarajarathnam divergingmechanismsofactivationofchemokinereceptorsrevealedbynovelchemokineagonists
AT javiernavarro divergingmechanismsofactivationofchemokinereceptorsrevealedbynovelchemokineagonists
_version_ 1725822469424545792